1
EPISODE · May 26, 2026 · 14 MIN
FDA Blocks Weight-Loss Drugs From Compounding Pharmacies as Supply Concerns Mount
from 1nessAgency Insights
The FDA's April 30, 2026 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list marks the most consequential regulatory shift in weight management marketing since these drugs entered the mainstream. For the clinics, telehealth platforms, and med sp
Embed this episode
NOW PLAYING
FDA Blocks Weight-Loss Drugs From Compounding Pharmacies as Supply Concerns Mount
0:00
14:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 1nessAgency Insights?
This episode is 14 minutes long.
When was this 1nessAgency Insights episode published?
This episode was published on May 26, 2026.
Can I download this 1nessAgency Insights episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!